Loading the page…
Nasdaq 100
MRNA
Moderna, Inc., Health Care
$221.72
−0.47% on the day
Close of Fri, Oct 30, 2026
+687.9% over 1Y
2025-10-302026-05-042026-10-30
Nasdaq 100
Moderna, Inc., Health Care
$221.72
−0.47% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145M | $389M | $678M | $1.0B | $142M | $108M | $966M | $1.9B |
| Gross margin | 35.9% | -145.5% | 33.3% | 79.6% | 16.2% | 16.7% | 23.5% | 72.4% |
| Operating margin | -562.1% | -356.8% | -126.4% | -25.6% | -638.7% | -972.2% | -129.0% | -3.8% |
| Net margin | -539.3% | -345.2% | -121.8% | -19.7% | -581.0% | -899.1% | -115.9% | 0.7% |
| EPS, diluted | −$1.97 | −$3.40 | −$2.10 | −$0.51 | −$2.13 | −$2.52 | −$2.91 | $0.03 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | MRNA | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | -3.6% | 3% |
| Book yield (book value ÷ price) | 7.6% | 34% |
| Free cash flow yield | -2.3% | 3% |
| Buyback yield | 0.0% | 29% |
| Revenue growth, a year | -39.9% | 0% |
| EPS growth, a year | 21.8% | 58% |
| Return on equity | -46.6% | 2% |
| Return on assets | -28.7% | 2% |
| Net margin | -141.4% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 2% |
| Liabilities ÷ assets | 38.3% | 29% |
|---|
| Past year, skipping last month | 664.9% | 99% |
|---|
| Past 6 months, skipping last month | 316.4% | 100% |
|---|
| Volatility, a year's worth | 366.3% | 100% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
From Yahoo Finance, modernatx.com
How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataSimply Wall St., 18h ago
This week in charts: ESMO’s winners and losersBioPharma Dive, Oct 30
Prediction markets herald insider trading risks for private biotechsPharmaceutical Technology, Oct 30
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineZacks, Oct 30
Merck & Co., Inc. Q3 Earnings Call HighlightsMarketBeat, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataSimply Wall St., 18h agoThis week in charts: ESMO’s winners and losersBioPharma Dive, Oct 30Prediction markets herald insider trading risks for private biotechsPharmaceutical Technology, Oct 30Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineZacks, Oct 30Merck & Co., Inc. Q3 Earnings Call HighlightsMarketBeat, Oct 30
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Oct. 28GuruFocus.com, Oct 30Invesco S&P 500 Equal Weight (RSP) Adds Moderna and PTC on Oct. 28GuruFocus.com, Oct 30
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.Barrons.com, Oct 29
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay AwayMotley Fool, Oct 29
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks, Oct 29Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Hoge StephenPresident | Option exercise | +76,452 | $12.21 | $933K | Form 4 ↗ |
| Oct 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −39,145 | $220.72 | $8.6M | Form 4 ↗ |
| Oct 14, 2026 | Hoge StephenPresident | Option exercise | +76,453 | $12.21 | $933K | Form 4 ↗ |
| Oct 14, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −39,224 | $213.48average | $8.4M | Form 4 ↗ |
| Oct 5, 2026 | Mock James MCFO | Units vested | +1,454 | — | — | Form 4 ↗ |
| Oct 5, 2026 | Mock James MCFO | Tax withholding | −704 | $190.01 | $134K | Form 4 ↗ |
| Sep 15, 2026 | Hoge StephenPresident | Option exercise | +76,452 | $12.21 | $933K | Form 4 ↗ |
| Sep 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −40,281 | $146.07 | $5.9M | Form 4 ↗ |
| Sep 14, 2026 | Hoge StephenPresident | Option exercise | +76,453 | $12.21 | $933K | Form 4 ↗ |
| Sep 14, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −40,294 | $144.13 | $5.8M | Form 4 ↗ |
| Sep 10, 2026 | Mock James MCFO | Option exercise | +19,836 | $30.96 | $614K | Form 4 ↗ |
| Sep 10, 2026 | Mock James MCFO | Sold on the market10b5-1 plan | −34,836 | $134.49 | $4.7M | Form 4 ↗ |
| Sep 4, 2026 | Mock James MCFO | Units vested | +11,797 | — | — | Form 4 ↗ |
| Sep 4, 2026 | Mock James MCFO | Tax withholding | −5,704 | $148.87 | $849K | Form 4 ↗ |
| Sep 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +11,797 | — | — | Form 4 ↗ |
| Sep 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,704 | $148.87 | $849K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Option exercise | +5,637 | $30.96 | $107K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Sold on the market10b5-1 plan | −3,471 | $139.95 | $486K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −1,048 | $140.34 | $147K | Form 4 ↗ |
| Sep 1, 2026 | Mock James MCFO | Units vested | +2,475 | — | — | Form 4 ↗ |
| Sep 1, 2026 | Mock James MCFO | Tax withholding | −1,197 | $140.34 | $168K | Form 4 ↗ |
| Sep 1, 2026 | Hoge StephenPresident | Units vested | +9,283 | — | — | Form 4 ↗ |
| Sep 1, 2026 | Hoge StephenPresident | Tax withholding | −4,489 | $140.34 | $630K | Form 4 ↗ |
| Aug 28, 2026 | Hoge StephenPresident | Units vested | +611 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Hoge StephenPresident | Tax withholding | −296 | $142.77 | $42.3K | Form 4 ↗ |
| Aug 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +329 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −160 | $142.77 | $22.8K | Form 4 ↗ |
| Aug 28, 2026 | Mock James MCFO | Units vested | +329 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Mock James MCFO | Tax withholding | −160 | $142.77 | $22.8K | Form 4 ↗ |
| Aug 27, 2026 | Hoge StephenPresident | Units vested | +1,437 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Hoge StephenPresident | Tax withholding | −695 | $149.66 | $104K | Form 4 ↗ |
| Aug 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +774 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −375 | $149.66 | $56.1K | Form 4 ↗ |
| Aug 27, 2026 | Mock James MCFO | Units vested | +774 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Mock James MCFO | Tax withholding | −375 | $149.66 | $56.1K | Form 4 ↗ |
| Aug 6, 2026 | Bancel StephaneCEO, Director | Option exercise | +252,469 | $19.15 | $4.8M | Form 4 ↗ |
| Aug 5, 2026 | Bancel StephaneCEO, Director | Option exercise | +499,246 | $19.15 | $9.6M | Form 4 ↗ |
| Aug 5, 2026 | Bancel StephaneCEO, Director | Sold on the market10b5-1 plan | −499,246 | $57.52average | $28.7M | Form 4 ↗ |
| Jul 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| Jul 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $67.60 | $3.6M | Form 4 ↗ |
| Jul 8, 2026 | McDonnell Michael R.Director | AwardStock Option (Right to Buy) | +7,415 | — | — | Form 4 ↗ |
| Jul 8, 2026 | McDonnell Michael R.Director | AwardRestricted Stock Units | +7,351 | — | — | Form 4 ↗ |
| Jul 5, 2026 | Banque Soria EsterChief Commercial Officer | AwardStock Option (Right to Buy) | +18,658 | — | — | Form 4 ↗ |
| Jul 5, 2026 | Banque Soria EsterChief Commercial Officer | AwardRestricted Stock Units | +38,364 | — | — | Form 4 ↗ |
| Jul 2, 2026 | Mock James MCFO | Units vested | +1,452 | — | — | Form 4 ↗ |
| Jul 2, 2026 | Mock James MCFO | Tax withholding | −703 | $72.50 | $51K | Form 4 ↗ |
| Jun 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| Jun 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $51.37 | $2.7M | Form 4 ↗ |
| Jun 5, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +11,798 | — | — | Form 4 ↗ |
| Jun 5, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,705 | $51.59 | $294K | Form 4 ↗ |
| Jun 5, 2026 | Mock James MCFO | Units vested | +11,798 | — | — | Form 4 ↗ |
| Jun 5, 2026 | Mock James MCFO | Tax withholding | −5,705 | $51.59 | $294K | Form 4 ↗ |
| Jun 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Option exercise | +3,471 | $30.96 | $107K | Form 4 ↗ |
| Jun 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Sold on the market10b5-1 plan | −3,471 | $50.00 | $174K | Form 4 ↗ |
| Jun 1, 2026 | Mock James MCFO | Units vested | +2,475 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Mock James MCFO | Tax withholding | −1,197 | $47.19 | $56.5K | Form 4 ↗ |
| Jun 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +2,165 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −1,047 | $47.19 | $49.4K | Form 4 ↗ |
| Jun 1, 2026 | Hoge StephenPresident | Units vested | +9,282 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Hoge StephenPresident | Tax withholding | −4,488 | $47.19 | $212K | Form 4 ↗ |
| May 28, 2026 | Mock James MCFO | Units vested | +328 | — | — | Form 4 ↗ |
| May 28, 2026 | Mock James MCFO | Tax withholding | −159 | $47.61 | $7.6K | Form 4 ↗ |
| May 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +328 | — | — | Form 4 ↗ |
| May 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −159 | $47.61 | $7.6K | Form 4 ↗ |
| May 28, 2026 | Hoge StephenPresident | Units vested | +610 | — | — | Form 4 ↗ |
| May 28, 2026 | Hoge StephenPresident | Tax withholding | −295 | $47.61 | $14K | Form 4 ↗ |
| May 27, 2026 | Mock James MCFO | Units vested | +773 | — | — | Form 4 ↗ |
| May 27, 2026 | Mock James MCFO | Tax withholding | −374 | $47.03 | $17.6K | Form 4 ↗ |
| May 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +773 | — | — | Form 4 ↗ |
| May 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −374 | $47.03 | $17.6K | Form 4 ↗ |
| May 27, 2026 | Hoge StephenPresident | Units vested | +1,437 | — | — | Form 4 ↗ |
| May 27, 2026 | Hoge StephenPresident | Tax withholding | −695 | $47.03 | $32.7K | Form 4 ↗ |
| May 21, 2026 | Afeyan NoubarDirector | Option exercise | +9,263 | $19.15 | $177K | Form 4 ↗ |
| May 21, 2026 | Afeyan NoubarDirector | Sold on the market | −9,263 | $46.84 | $434K | Form 4 ↗ |
| May 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| May 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $48.40 | $2.6M | Form 4 ↗ |
| May 6, 2026 | Rubenstein David M.Director | AwardStock Option (Right to Buy) | +9,681 | — | — | Form 4 ↗ |
| May 6, 2026 | Rubenstein David M.Director | AwardRestricted Stock Units | +2,092 | — | — | Form 4 ↗ |
| May 6, 2026 | Hussain AbbasDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Horning SandraDirector | AwardStock Option (Right to Buy) | +9,681 | — | — | Form 4 ↗ |
| May 6, 2026 | Horning SandraDirector | AwardRestricted Stock Units | +2,092 | — | — | Form 4 ↗ |
| May 6, 2026 | Nabel Elizabeth GDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Nader FrancoisDirector | AwardStock Option (Right to Buy) | +6,454 | — | — | Form 4 ↗ |
| May 6, 2026 | Nader FrancoisDirector | AwardRestricted Stock Units | +4,185 | — | — | Form 4 ↗ |
| May 6, 2026 | Tallett Elizabeth EDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Afeyan NoubarDirector | AwardStock Option (Right to Buy) | +12,908 | — | — | Form 4 ↗ |
| May 1, 2026 | Hussain AbbasDirector | Sold on the market10b5-1 plan | −5,682 | $46.63 | $265K | Form 4 ↗ |
| Apr 30, 2026 | Horning SandraDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Rubenstein David M.Director | Units vested | +8,116 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Hussain AbbasDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Nabel Elizabeth GDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Nader FrancoisDirector | Units vested | +12,174 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Beat the forecast in 3 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.